Evidence map›Paper›PMID 37503050›Full record

ArticlebioRxiv : the preprint server for biology2023

De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression.

Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Peter Sajjakulnukit, Maureen A Lyons and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Naveen Kumar TanguduDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Raquel BujDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Hui WangDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Jiefei WangDepartment of Biomedical Informatics and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Aidan R ColeDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Apoorva UbovejaDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Richard FangDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Amandine AmalricDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Peter SajjakulnukitDepartment of Molecular and Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology, and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Maureen A LyonsGenomics Facility UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Kristine CooperBiostatistics Facility UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Nadine HempelDivision of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
Nathaniel W SnyderDepartment of Cardiovascular Sciences, Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
Costas A LyssiotisDepartment of Molecular and Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology, and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Uma R ChandranDepartment of Biomedical Informatics and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Katherine M AirdDepartment of Pharmacology & Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
University of Pittsburgh · USUPMC Hillman Cancer Center · USMichigan Medicine · USTemple University · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancerR01CA259111 · NCI · WISTAR INSTITUTE · PI AIRD, KATHERINE MARIE, SNYDER, NATHANIEL W. · 2021 to 2025
$2.9M
Investigating p16 Loss in Pro-tumorigenic MetabolismR37CA240625 · NCI · WISTAR INSTITUTE · PI AIRD, KATHERINE MARIE · 2020 to 2025
$2.6M
Predoctoral Training in Pharmacological Sciences (Resubmission)T32GM133332 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tija C. Jacob, Francisco Jose Schopfer · 2020 to 2026
$1.8M
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA259111NCI NIH HHS R37 CA240625NIGMS NIH HHS T32 GM133332
6 · The paper itself

Abstract

p16 is a tumor suppressor encoded by the

Indexed as

anti-folatesanti-metabolitesfolate metabolismmelanomaone carbon metabolism

Identifiers

PMID37503050
PMCPMC10369956
OpenAlexW4384405221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.